The relationship between the results of in silico and in vivo studies of hypoglycemic, hypolipidemic, hepatoprotective properties of a new 1,4-dihydropyridine derivative

Objective: determination of the relationship between the results of in silico and in vivo studies of hypoglycemic, hypolipidemic, hepatoprotective properties of a new 1,4-dihydropyridine derivative coded AZ-383. Material and methods. Virtual bioscreening of compound AZ-383 was carried out using Swiss Target Prediction programs. The identified biotargets were promising for the pharmacocorrection of a complex of metabolic disorders, which was confirmed in an experiment conducted on male Wistar rats. In vivo, the levels of glucose, total cholesterol, triglycer-ides, ALT, AST, and total bilirubin in the blood were studied; the microarchitecture of the rat liver was assessed after pharmacocorrection of simulated metabolic disorders with the compound AZ-383. Results. The presence of hypogly-cemic, hypolipidemic, hepatoprotective activity, and a positive effect on body weight in the compound AZ-383 was revealed. The glucose level reached 7.9±0.4 mmol/l. The body weight of rats after application of AZ-383 was at the level of 378±12 g. Under the influence of AZ-383, an increase in the number of hepatocytes was noted by 17.8%, a decrease in the size of hepatocytes by 7%, a decrease in the area of the cytoplasm and nuclei of hepatocytes by 5.2 and 18.7%, respectively, relative to the control group of animals. Conclusion. An in vivo experiment confirmed the presence of hypoglycemic, hypolipidemic, and hepatoprotective properties in compound AZ-383, which corresponds to the biotargets determined in silico for this 1,4-dihydropyridine derivative.